Intravenous immunoglobulin bridging to rituximab in NMDAR encephalitis patients non-responders to first-line treatments
Background The immunotherapy strategy for autoimmune encephalitis is based on several types and schedules of both first- and second-line drugs. Failing to respond to the latter prompts the use of non-conventional rescue therapies, with higher risks of severe adverse effects. We report on a protocol that entails the use of intravenous immunoglobulin cycles to bridge the 4-month period that the second-line drug rituximab needs to exert its full therapeutic effects. Methods Three patients with NMDAR encephalitis who were non-responders to first-line treatments entered the study. The protocol consisted of six monthly cycles of intravenous immunoglobulins (IVIG, 0.4 mg/kg/die for 5 days), starting 1 month after the last rituximab infusion (1000 mg at days 0 and 15). Brain MRI and [18F]-FDG-PET were performed at onset and at six and 18 months after onset. Results In the three patients, substantial improvements of disability or complete recovery were achieved, without modifications over the 30-to-50-month follow-up. No adverse events nor laboratory test abnormalities were recorded. Imaging findings paralleled the favorable disease courses. Brain [18F]-FDG-PET was more sensitive than MRI in detecting abnormalities. Discussion Our observations suggest that the herein-described protocol might be used in patients with NMDAR encephalitis at risk for poor prognosis in the mid-term when they need to shift to rituximab. [18F]-FDG-PET confirmed to be a sensitive tool to detect the minimal brain lesions that can underlie isolated cognitive and psychiatric symptoms..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
Neurological sciences - 43(2022), 11 vom: 11. Aug., Seite 6441-6447 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Massa, Federico [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Autoimmune diseases |
|---|
| Anmerkungen: |
© The Author(s) 2022 |
|---|
| doi: |
10.1007/s10072-022-06313-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR04848086X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR04848086X | ||
| 003 | DE-627 | ||
| 005 | 20230519075809.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 221029s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10072-022-06313-3 |2 doi | |
| 035 | |a (DE-627)SPR04848086X | ||
| 035 | |a (SPR)s10072-022-06313-3-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Massa, Federico |e verfasserin |0 (orcid)0000-0001-5667-204X |4 aut | |
| 245 | 1 | 0 | |a Intravenous immunoglobulin bridging to rituximab in NMDAR encephalitis patients non-responders to first-line treatments |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2022 | ||
| 520 | |a Background The immunotherapy strategy for autoimmune encephalitis is based on several types and schedules of both first- and second-line drugs. Failing to respond to the latter prompts the use of non-conventional rescue therapies, with higher risks of severe adverse effects. We report on a protocol that entails the use of intravenous immunoglobulin cycles to bridge the 4-month period that the second-line drug rituximab needs to exert its full therapeutic effects. Methods Three patients with NMDAR encephalitis who were non-responders to first-line treatments entered the study. The protocol consisted of six monthly cycles of intravenous immunoglobulins (IVIG, 0.4 mg/kg/die for 5 days), starting 1 month after the last rituximab infusion (1000 mg at days 0 and 15). Brain MRI and [18F]-FDG-PET were performed at onset and at six and 18 months after onset. Results In the three patients, substantial improvements of disability or complete recovery were achieved, without modifications over the 30-to-50-month follow-up. No adverse events nor laboratory test abnormalities were recorded. Imaging findings paralleled the favorable disease courses. Brain [18F]-FDG-PET was more sensitive than MRI in detecting abnormalities. Discussion Our observations suggest that the herein-described protocol might be used in patients with NMDAR encephalitis at risk for poor prognosis in the mid-term when they need to shift to rituximab. [18F]-FDG-PET confirmed to be a sensitive tool to detect the minimal brain lesions that can underlie isolated cognitive and psychiatric symptoms. | ||
| 650 | 4 | |a Autoimmune diseases |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Intravenous immunoglobulins |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Modified-Rankin scale |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a NMDAR encephalitis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Rituximab |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a CASE score |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Franciotta, Diego |4 aut | |
| 700 | 1 | |a Grisanti, Stefano |4 aut | |
| 700 | 1 | |a Roccatagliata, Luca |4 aut | |
| 700 | 1 | |a Morbelli, Silvia |4 aut | |
| 700 | 1 | |a Beltramini, Sabrina |4 aut | |
| 700 | 1 | |a Uccelli, Antonio |4 aut | |
| 700 | 1 | |a Schenone, Angelo |4 aut | |
| 700 | 1 | |a Benedetti, Luana |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neurological sciences |d Milano : Springer, 2000 |g 43(2022), 11 vom: 11. Aug., Seite 6441-6447 |w (DE-627)SPR008581010 |w (DE-600)1481772-X |x 1590-3478 |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2022 |g number:11 |g day:11 |g month:08 |g pages:6441-6447 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10072-022-06313-3 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 2022 |e 11 |b 11 |c 08 |h 6441-6447 | ||